Background
Clopidogrel is a prodrug — it needs the liver enzyme CYP2C19 to activate it into its effective form before it can inhibit platelets. The problem: a large share of Vietnamese and East Asian people carry reduced-function CYP2C19 variants (commonly the *2, *3 alleles). In these people clopidogrel is poorly activated, its antiplatelet effect is weak, and the risk of in-stent thrombosis rises, especially after acute coronary syndrome or a coronary intervention.
The situation (illustrative patient)
Male, 58, post-stent for myocardial infarction. Pharmacogenomic test: CYP2C19 *2/*2 — poor metabolizer. The physician’s question: is it safe to continue clopidogrel, and if we switch, to what, and how strong is the evidence?
The physician asks Phở one question
Within seconds, Phở returns a structured, sourced answer:
- For poor/intermediate metabolizer phenotypes after a coronary intervention, CPIC guidance prefers a CYP2C19-independent alternative — prasugrel or ticagrelor (absent contraindications).
- The FDA carries a boxed warning about reduced clopidogrel efficacy in poor metabolizers.
- Each point carries a real citation (CPIC guideline, PubMed article) and a level of evidence (GRADE); where the literature is unsettled, it is labelled “insufficient evidence” rather than stated with false certainty.
What makes it different
A typical chatbot can answer fluently but fabricate a source or overstate certainty. Phở does the opposite: every claim must have a real source or admit it’s unsure — measured at roughly 88.5% of answers backed by a source. For a decision like switching antiplatelet therapy after a stent, that’s not a nice-to-have; it’s the minimum bar for trust.
An honest boundary. Phở does not replace the physician’s decision, and does not run raw sequencing pipelines. It does the interpretation, evidence synthesis, and lookup: turning a dry genetic result into sourced clinical context, so the physician decides faster and with more confidence.
Reproduce this flow
- Open Phở and select Clinical Mode.
- Type a real question: “Post-stent patient, CYP2C19 *2/*2 (poor metabolizer). Is clopidogrel still effective, and what should we switch to? Evidence level?”
- Watch Phở run its phases (semantic async): resolving-intent → retrieving (N sources) → synthesizing → citing.
- Read the structured answer: recommendation, alternative drugs, GRADE level, with
[1] [2]markers inline. - Click a citation
[N]to open the real source in the SourceRail (CPIC/PubMed, with a link). - Note a claim labelled “insufficient evidence” (if any) — Phở dares to say “not sure”.
The message throughout: click anywhere and you get a real source.
Features showcased — true status
| Feature | Role in this case | Status |
|---|---|---|
| Clinical Mode / research-grounded answer | Clinical answer with GRADE + citations | ✅ built |
| Grounded retrieval (PubMed/OpenAlex/Europe PMC) | Fetches real guidance + literature | ✅ live |
Inline citations [N] + SourceRail | Click to a real source, adjacency | ✅ live |
| Cite-or-abstain / groundedness ~88.5% | No fabrication; labels “unverified” | ✅ live |
| ChEMBL drug-gene / mechanism | Drug–gene interaction lookup | 🟡 coming |
Bottom line: the patient’s genes were already on the report. What was missing was the time and evidence to read them right there at the bedside. That’s where Phở stands.